
|Articles|May 1, 2002
FDA approval has derms jumping for joy - some a little too high
The drug that pleases by paralysis is no reason to party, even in the wake of FDA approval.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Grants Breakthrough Therapy Designation to Litifilimab for Cutaneous Lupus Erythematosus
2
Del Rosso's What's New in the Medicine Chest 2026: CHE, CSU, and Vitiligo
3
Multi-Ingredient Topical Treatment Significantly Improves Wrinkles and Skin Thickness in Patients with "Ozempic Face"
4
Beyond Weight Loss: Clinical Perspectives on GLP-1s for Inflammatory Dermatoses
5










